Avalo Therapeutics, Inc.
AVTX
$18.20
$0.201.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 59.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 59.00K | -- | -- | -- |
| Cost of Revenue | 10.15M | 8.78M | 9.99M | 10.66M | 5.91M |
| Gross Profit | -10.15M | -8.73M | -9.99M | -10.66M | -5.91M |
| SG&A Expenses | 6.85M | 6.53M | 5.58M | 5.24M | 5.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.90M | 19.80M | 19.20M | 19.32M | 14.67M |
| Operating Income | -20.90M | -19.74M | -19.20M | -19.32M | -14.67M |
| Income Before Tax | -19.62M | -13.59M | -30.61M | -20.75M | -13.14M |
| Income Tax Expenses | 12.00K | 130.00K | 11.00K | 16.00K | 8.00K |
| Earnings from Continuing Operations | -19.63M | -13.72M | -30.63M | -20.77M | -13.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.63M | -13.72M | -30.63M | -20.77M | -13.15M |
| EBIT | -20.90M | -19.74M | -19.20M | -19.32M | -14.67M |
| EBITDA | -20.88M | -19.73M | -19.14M | -19.18M | -14.53M |
| EPS Basic | -0.98 | -0.75 | -2.19 | -1.92 | -1.25 |
| Normalized Basic EPS | -0.61 | -0.47 | -1.37 | -1.20 | -0.78 |
| EPS Diluted | -0.98 | -0.75 | -2.19 | -1.92 | -1.25 |
| Normalized Diluted EPS | -0.61 | -0.47 | -1.37 | -1.20 | -0.78 |
| Average Basic Shares Outstanding | 20.11M | 18.23M | 14.00M | 10.83M | 10.51M |
| Average Diluted Shares Outstanding | 20.11M | 18.23M | 14.00M | 10.83M | 10.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |